Mometasone Ointment Formulation

1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Mometasone Ointment Formulation

Manufacturer or supplier's details
Company: MSD
Address: 199 Wenhai North Road
          HEDA, Hangzhou - Zhejiang Province - CHINA 310018
Telephone: 908-740-4000
Emergency telephone number: 86-571-87268110
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview
Appearance: ointment
Colour: white to off-white
Odour: No data available
Causes serious eye irritation. Toxic to aquatic life with long lasting effects.

GHS Classification
Serious eye damage/eye irritation: Category 2A
Long-term (chronic) aquatic hazard: Category 2

GHS label elements
Hazard pictograms: 

Signal word: Warning
Hazard statements: H319 Causes serious eye irritation.
H411 Toxic to aquatic life with long lasting effects.
Precautionary statements: Prevention:
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear eye protection/ face protection.
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Mometasone Ointment Formulation

Response:
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337 + P313 If eye irritation persists: Get medical advice/attention.
P391 Collect spillage.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
Causes serious eye irritation.

Environmental hazards
Toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixture</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrolatum</td>
<td>8009-03-8</td>
<td>&gt;= 70 -&lt; 90</td>
</tr>
<tr>
<td>2-Methyl-2,4-pentanediol</td>
<td>107-41-5</td>
<td>&gt;= 10 -&lt; 20</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>&gt;= 0.1 -&lt; 0.25</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
Mometasone Ointment Formulation

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes serious eye irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Vapours may form explosive mixtures with air.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
7. HANDLING AND STORAGE

Handling
Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling: Do not get on skin or clothing.
Do not swallow.
Do not get in eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage
Conditions for safe storage: Keep in properly labelled containers.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types:
Strong oxidizing agents

Packaging material: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrolatum</td>
<td>8009-03-8</td>
<td>TWA (Inhalable fraction)</td>
<td>5 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>2-Methyl-2,4-pentanediol</td>
<td>107-41-5</td>
<td>MAC</td>
<td>100 mg/m³</td>
<td>GBZ 2.1-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Vapour)</td>
<td>25 ppm</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL (Vapour)</td>
<td>50 ppm</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL (Inhalable fraction, Aerosol only)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td>Further information: Skin</td>
<td></td>
<td>Wipe limit</td>
<td>10 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of
the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

**Personal protective equipment**

- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- **Filter type**: Combined particulates and organic vapour type
- **Eye/face protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- **Skin and body protection**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
- **Hand protection**: Chemical-resistant gloves

**Remarks**: Consider double gloving.

**Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

- **Appearance**: ointment
- **Colour**: white to off-white
- **Odour**: No data available
- **Odour Threshold**: No data available
- **pH**: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: > 93.3 °C
Evaporation rate: No data available
Flammability (solid, gas): Not classified as a flammability hazard
Flammability (liquids): Not applicable
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
Density: No data available
Solubility(ies)
  Water solubility: No data available
Partition coefficient: n-octanol/water: No data available
Auto-ignition temperature: No data available
Decomposition temperature: No data available
Viscosity
  Viscosity, kinematic: No data available
Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: No data available

**10. STABILITY AND REACTIVITY**

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Mometasone Ointment Formulation

Possibility of hazardous reactions:
- Vapours may form explosive mixture with air.
- Can react with strong oxidizing agents.

Conditions to avoid:
- None known.

Incompatible materials:
- Oxidizing agents

Hazardous decomposition products:
- No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes:
- Skin contact
- Ingestion
- Eye contact

Acute toxicity:
Not classified based on available information.

Product:
Acute oral toxicity:
- Acute toxicity estimate: > 5,000 mg/kg
- Method: Calculation method

Components:

Petrolatum:
Acute oral toxicity:
- LD50 (Rat): > 5,000 mg/kg
- Method: OECD Test Guideline 401
- Remarks: Based on data from similar materials

Acute dermal toxicity:
- LD50 (Rat): > 2,000 mg/kg
- Method: OECD Test Guideline 402
- Assessment: The substance or mixture has no acute dermal toxicity
- Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Acute oral toxicity:
- LD50 (Rat): > 2,000 mg/kg

Acute dermal toxicity:
- LD50 (Rat): > 2,000 mg/kg
- Method: OECD Test Guideline 402
- Assessment: The substance or mixture has no acute dermal toxicity

Mometasone:
Acute oral toxicity:
- LD50 (Rat): > 2,000 mg/kg
- LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity:
- LC50 (Rat): > 3.3 mg/l
- Exposure time: 4 h
- Test atmosphere: dust/mist
- Remarks: No mortality observed at this dose.
- LC50 (Mouse): > 3.2 mg/l
**Mometasone Ointment Formulation**

**Exposure time:** 4 h  
**Test atmosphere:** dust/mist

**Acute toxicity (other routes of administration):**  
**LD50 (Rat):** 300 mg/kg  
**Application Route:** Subcutaneous  
**Symptoms:** Breathing difficulties

**Skin corrosion/irritation**  
Not classified based on available information.

**Components:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Species</th>
<th>Method</th>
<th>Result</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrolatum</td>
<td>Rabbit</td>
<td>OECD Test Guideline 404</td>
<td>No skin irritation</td>
<td>Based on data from similar materials</td>
</tr>
<tr>
<td>2-Methyl-2,4-pentanediol</td>
<td>Rabbit</td>
<td>OECD Test Guideline 404</td>
<td>No skin irritation</td>
<td></td>
</tr>
<tr>
<td>Mometasone</td>
<td>Rabbit</td>
<td></td>
<td>No skin irritation</td>
<td></td>
</tr>
</tbody>
</table>

**Serious eye damage/eye irritation**  
Causes serious eye irritation.

**Components:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Species</th>
<th>Method</th>
<th>Result</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrolatum</td>
<td>Rabbit</td>
<td>OECD Test Guideline 405</td>
<td>No eye irritation</td>
<td>Based on data from similar materials</td>
</tr>
<tr>
<td>2-Methyl-2,4-pentanediol</td>
<td>Rabbit</td>
<td></td>
<td>Irritation to eyes, reversing within 21 days</td>
<td></td>
</tr>
<tr>
<td>Mometasone</td>
<td>Rabbit</td>
<td></td>
<td>No eye irritation</td>
<td></td>
</tr>
</tbody>
</table>

**Respiratory or skin sensitisation**

**Skin sensitisation**  
Not classified based on available information.
Mometasone Ointment Formulation

Respiratory sensitisation
Not classified based on available information.

Components:

Petrolatum:
Test Type: Buehler Test
Exposure routes: Skin contact
Species: Guinea pig
Result: negative
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative

Mometasone:
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Assessment: Does not cause skin sensitisation.
Result: negative
Remarks: The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

Germ cell mutagenicity
Not classified based on available information.

Components:

Petrolatum:
Genotoxicity in vitro: Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Mometasone:  
Genotoxicity in vitro  
Result: negative  
Test Type: Chromosome aberration test in vitro  
Result: negative  

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  

Test Type: Chromosomal aberration  
Test system: Chinese hamster lung cells  
Result: negative  

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: positive  

Test Type: Mouse Lymphoma  
Result: negative  

Genotoxicity in vivo  
Result: negative  
Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative  

Test Type: Chromosomal aberration  
Species: Rat  
Cell type: Bone marrow  
Result: negative  

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Result: negative  

Germ cell mutagenicity - Assessment  
Weight of evidence does not support classification as a germ cell mutagen.  

Carcinogenicity  
Not classified based on available information.  

Components:  

Petrolatum:  
Species  
: Rat  
Application Route  
: Ingestion  
Exposure time  
: 2 Years  
Result  
: negative  

Mometasone:  
Species  
: Rat  
Application Route  
: Inhalation
Mometasone Ointment Formulation

--

**Exposure time** : 2 Years  
**Dose** : 0.067 mg/kg body weight  
**Result** : negative

**Species** : Mouse  
**Application Route** : Inhalation  
**Exposure time** : 19 Months  
**Dose** : 0.160 mg/kg body weight  
**Result** : negative

---

**Reproductive toxicity**

Not classified based on available information.

**Components:**

**Petrolatum:**

**Effects on fertility** : Test Type: Reproduction/Developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**Effects on foetal development** : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Skin contact  
Result: negative  
Remarks: Based on data from similar materials

---

**2-Methyl-2,4-pentanediol:**

**Effects on fertility** : Test Type: Reproduction/Developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 421  
Result: negative

**Effects on foetal development** : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 414  
Result: negative

---

**Mometasone:**

**Effects on fertility** : Test Type: Fertility  
Species: Rat  
Application Route: Subcutaneous  
Fertility: NOAEL: 0.015 mg/kg body weight  
Symptoms: Reduced embryonic survival, Reduced foetal weight  
Result: No effects on fertility, Effect on reproduction capacity
## Mometasone Ointment Formulation

**SAFETY DATA SHEET**

according to GB/T 16483 and GB/T 17519

<table>
<thead>
<tr>
<th>Version</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.5</td>
<td>1751211-00006</td>
<td>2019/04/24</td>
<td>2017/06/14</td>
</tr>
</tbody>
</table>

### Effects on foetal development

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Mouse</td>
</tr>
<tr>
<td>Application Route: Subcutaneous</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Embryotoxic effects., Teratogenicity and developmental toxicity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Dermal</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Embryo-foetal toxicity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Application Route: Dermal</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Effects on newborn</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Subcutaneous</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Embryo-foetal toxicity, Malformations were observed.</td>
</tr>
</tbody>
</table>

### Reproductive toxicity - Assessment

| Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments. |

### STOT - single exposure

Not classified based on available information.

### Components:

#### Mometasone:

### STOT - repeated exposure

Not classified based on available information.

### Components:

#### Mometasone:

<table>
<thead>
<tr>
<th>Exposure routes: inhalation (dust/mist/fume)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Organs: Immune system, Liver, Kidney, Skin</td>
</tr>
<tr>
<td>Assessment: May cause damage to organs through prolonged or repeated exposure.</td>
</tr>
</tbody>
</table>
### Repeated dose toxicity

**Components:**

**Petrolatum:**
- **Species:** Rat
- **NOAEL:** 5,000 mg/kg
- **Application Route:** Ingestion
- **Exposure time:** 2 yr

**2-Methyl-2,4-pentanediol:**
- **Species:** Rat
- **NOAEL:** >= 450 mg/kg
- **Application Route:** Ingestion
- **Exposure time:** 90 Days
- **Method:** OECD Test Guideline 408

**Mometasone:**
- **Species:** Rat
- **NOAEL:** 0.005 mg/kg
- **LOAEL:** 0.3 mg/kg
- **Application Route:** Oral
- **Exposure time:** 30 d
- **Target Organs:** Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

- **Species:** Dog
- **NOAEL:** 0.5 mg/kg
- **Application Route:** Oral
- **Exposure time:** 30 d
- **Target Organs:** Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

- **Species:** Rat
- **NOAEL:** 0.00013 mg/l
- **Application Route:** inhalation (dust/mist/fume)
- **Exposure time:** 90 d
- **Target Organs:** Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

- **Species:** Dog
- **NOAEL:** 0.0005 mg/l
- **Application Route:** inhalation (dust/mist/fume)
- **Exposure time:** 90 d
- **Target Organs:** Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

**Aspiration toxicity**
Not classified based on available information.
Mometasone Ointment Formulation

**Components:**

**Mometasone:**
Not applicable

**Experience with human exposure**

**Components:**

2-Methyl-2,4-pentanediol:

Eye contact: Target Organs: Eyes
Symptoms: Irritation

**Mometasone:**
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact: Symptoms: Dermatitis, Itching

**Further information**

**Components:**

**Mometasone:**
Remarks: Dermal absorption possible

**12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**

Petrolatum:

Toxicity to fish: LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 10,000 mg/l
Exposure time: 48 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants: NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates (Chronic): NOEC (Daphnia magna (Water flea)): 10 mg/l
Exposure time: 21 d
ic toxicity) Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Toxicity to fish: LC50 (Gambusia affinis (Mosquito fish)): 8,510 mg/l Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Ceriodaphnia dubia (water flea)): 2,800 mg/l Exposure time: 48 h

Toxicity to algae/aquatic plants: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

EC10 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

Toxicity to microorganisms: NOEC: 200 mg/l Exposure time: 10 d

Mometasone:
Toxicity to fish: LC50 (Menidia beryllina (Silverside)): 0.11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheephead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Mometasone Ointment Formulation

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC (Daphnia magna (Water flea)): 0.34 mg/l
- Exposure time: 21 d
- Method: OECD Test Guideline 211
- Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity):
- NOEC: 1,000 mg/l
- Exposure time: 3 h
- Test Type: Respiration inhibition
- Method: OECD Test Guideline 209
- Remarks: No toxicity at the limit of solubility

Exposure time:
- 21 d
- 3 h

Persistence and degradability

Components:

Petrolatum:
- Biodegradability: Result: Not readily biodegradable.
- Biodegradation: 31 %
- Exposure time: 28 d
- Method: OECD Test Guideline 301F
- Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
- Biodegradability: Result: Readily biodegradable.
- Biodegradation: 81 %
- Exposure time: 28 d
- Method: OECD Test Guideline 301F

Mometasone:
- Biodegradability: Result: Not readily biodegradable.
- Biodegradation: 50 %
- Exposure time: 28 d
- Method: OECD Test Guideline 314

Stability in water:
- Hydrolysis: 50 % (12 d)
- Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

2-Methyl-2,4-pentanediol:
- Partition coefficient: n-octanol/water: log Pow: 0
- Remarks: Calculation
Mometasone Ointment Formulation

Mometasone:
Bioaccumulation
Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water
log Pow: 4.68

Mobility in soil

Components:
Mometasone:
Distribution among environmental compartments
log Koc: 4.02

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class: 9
Packing group: III
Labels: 9

IATA-DGR
UN/ID No.: UN 3077
Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Mometasone)
Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 956
Packing instruction (passenger aircraft): 956
Environmentally hazardous: yes
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Mometasone Ointment Formulation

Version 1.5  |  Revision Date: 09/13/2019  |  SDS Number: 1751211-00006  |  Date of last issue: 2019/04/24
          |                             |                             |  Date of first issue: 2017/06/14

IMDG-Code
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

GB 6944/12268
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class : 9
Packing group : III
Labels : 9

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

National regulatory information
Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

Further information
Date format : yyyy/mm/dd

18 / 19
Mometasone Ointment Formulation

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average
ACGIH / STEL : Short-term exposure limit
GBZ 2.1-2007 / MAC : Maximum allowable concentration

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.